UNLABELLED: We sought to determine if complete pathological necrosis (pathCR) predicts favorable oncological outcome in soft tissue sarcoma (STS) patients receiving pre-operative radiation monotherapy (RT). PATIENTS AND METHODS: We evaluated 30 patients with primary STS treated with neoadjuvant RT followed by definitive resection, from 2000 to 2010 at our institution. We defined ≥ 95% tumor necrosis as pathCR. RESULTS: There were 22 STS of the extremities (73%), 7 of the retroperitoneum (23%), and 1 (4%) of the trunk. The median pathological percentage of tumor necrosis was 35% (range 5-100%) with three tumors (10%) demonstrating pathCR. With a median follow-up of 40 months, the 5-year local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and overall survival (OS) for the entire cohort were 100%, 61% ± 11%, and 69% ± 11%, respectively. Among patients with pathCR, 3-year DRFS was 100% compared to 63±11% in patients without pathCR (p=0.28). CONCLUSION: Following neoadjuvant RT for STS, pathCR is associated with a clinically but not statistically significant 37% improvement in 3-year DRFS.
UNLABELLED: We sought to determine if complete pathological necrosis (pathCR) predicts favorable oncological outcome in soft tissue sarcoma (STS) patients receiving pre-operative radiation monotherapy (RT). PATIENTS AND METHODS: We evaluated 30 patients with primary STS treated with neoadjuvant RT followed by definitive resection, from 2000 to 2010 at our institution. We defined ≥ 95% tumor necrosis as pathCR. RESULTS: There were 22 STS of the extremities (73%), 7 of the retroperitoneum (23%), and 1 (4%) of the trunk. The median pathological percentage of tumor necrosis was 35% (range 5-100%) with three tumors (10%) demonstrating pathCR. With a median follow-up of 40 months, the 5-year local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and overall survival (OS) for the entire cohort were 100%, 61% ± 11%, and 69% ± 11%, respectively. Among patients with pathCR, 3-year DRFS was 100% compared to 63±11% in patients without pathCR (p=0.28). CONCLUSION: Following neoadjuvant RT for STS, pathCR is associated with a clinically but not statistically significant 37% improvement in 3-year DRFS.
Authors: F C Eilber; G Rosen; J Eckardt; C Forscher; S D Nelson; M Selch; F Dorey; F R Eilber Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: P Picci; T Böhling; G Bacci; S Ferrari; L Sangiorgi; M Mercuri; P Ruggieri; M Manfrini; A Ferraro; R Casadei; M S Benassi; A F Mancini; P Rosito; A Cazzola; E Barbieri; A Tienghi; A Brach del Prever; A Comandone; P Bacchini; F Bertoni Journal: J Clin Oncol Date: 1997-04 Impact factor: 44.544
Authors: J C Yang; A E Chang; A R Baker; W F Sindelar; D N Danforth; S L Topalian; T DeLaney; E Glatstein; S M Steinberg; M J Merino; S A Rosenberg Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: D A Potter; J Glenn; T Kinsella; E Glatstein; E E Lack; C Restrepo; D E White; C A Seipp; R Wesley; S A Rosenberg Journal: J Clin Oncol Date: 1985-03 Impact factor: 44.544
Authors: Thomas F DeLaney; Ira J Spiro; Herman D Suit; Mark C Gebhardt; Francis J Hornicek; Henry J Mankin; Andrew L Rosenberg; Daniel I Rosenthal; Fariba Miryousefi; Marcus Ancukiewicz; David C Harmon Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-15 Impact factor: 7.038
Authors: Kelly K Curtis; Jonathan B Ashman; Christopher P Beauchamp; Adam J Schwartz; Matthew D Callister; Amylou C Dueck; Leonard L Gunderson; Tom R Fitch Journal: Radiat Oncol Date: 2011-08-09 Impact factor: 3.481
Authors: William W Tseng; Shouhao Zhou; Christina A To; Peter F Thall; Alexander J Lazar; Raphael E Pollock; Patrick P Lin; Janice N Cormier; Valerae O Lewis; Barry W Feig; Kelly K Hunt; Matthew T Ballo; Shreyaskumar Patel; Peter W T Pisters Journal: Cancer Date: 2015-07-15 Impact factor: 6.860
Authors: Rick L M Haas; Aisha B Miah; Cécile LePechoux; Thomas F DeLaney; Elizabeth H Baldini; Kaled Alektiar; Brian O'Sullivan Journal: Radiother Oncol Date: 2015-12-21 Impact factor: 6.280
Authors: Mio Yanagisawa; Alicia A Gingrich; Sean Judge; Chin-Shang Li; Nana Wang; Steven W Thorpe; Amanda R Kirane; Richard J Bold; Arta M Monjazeb; Robert J Canter Journal: Anticancer Res Date: 2018-03 Impact factor: 2.480
Authors: Christian Isaac; John Kavanagh; Anthony Michael Griffin; Colleen I Dickie; Rakesh Mohankumar; Peter W Chung; Charles N Catton; David Shultz; Peter C Ferguson; Jay S Wunder Journal: Br J Radiol Date: 2021-12-03 Impact factor: 3.039
Authors: Robert J Canter; Dariusz Borys; Abimbola Olusanya; Chin-Shang Li; Li-Yuan Lee; Robert D Boutin; Scott D Christensen; Robert M Tamurian; Arta M Monjazeb Journal: Ann Surg Oncol Date: 2014-02-20 Impact factor: 5.344
Authors: Sneha R Rao; Alexander L Lazarides; Bruce L Leckey; Whitney O Lane; Julia D Visgauss; Jason A Somarelli; David G Kirsch; Nicole A Larrier; Brian E Brigman; Dan G Blazer; Diana M Cardona; William C Eward Journal: Cancer Med Date: 2021-11-27 Impact factor: 4.452
Authors: Jill Remick; William Regine; Robert Malyapa; Vincent Ng; Melissa Vyfhuis; Tejan Diwanji; Susan Shyu; James W Snider Journal: Cureus Date: 2017-09-15